REG - Sareum Holdings PLC - Issue of RiverFort Subscription Shares

Sareum HoldingsAnnouncement

19/04/2024 11:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240419:nRSS3583La&default-theme=true

RNS Number : 3583L  Sareum Holdings PLC  19 April 2024

Sareum Holdings plc

("Sareum" or the "Company")

 

Issue of RiverFort Subscription Shares

 

Cambridge, UK, 19 April 2024 - Sareum Holdings plc (AIM: SAR), a
clinical-stage biotechnology company developing next-generation kinase
inhibitors for autoimmune disease and cancer, announces that it has issued
3,000,000 new Ordinary Shares in the capital of the Company to RiverFort
Global Opportunities PCC Ltd ("RiverFort"), in accordance with the terms of
the Facility as announced on 3 August 2023.

 

The Company has an outstanding balance of circa £0.22 million under the
Facility. Any balances pursuant to the Facility are not due for repayment
until August 2025 (the "Maturity Date") and the Company expects to settle all
balances by the issuance of Subscription Shares prior to the Maturity Date.

 

As noted in Sareum's announcement of 28 March 2024, the Company does not
intend to make any further withdrawals pursuant to the Facility with
RiverFort.

 

Admission and Total Voting Rights

Application has been made to the London Stock Exchange plc for the admission
of 3,000,000 new Ordinary Shares to trading on AIM ("Admission"). It is
expected that Admission will occur at 8.00 a.m. (London time) on or around
Wednesday 24 April 2024.

Immediately following Admission, the total number of Ordinary Shares in issue
will be 104,578,309 and the total number of voting rights will therefore be
104,578,309, and this figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the share capital
of the Company under the FCA's Disclosure and Transparency Rules.

Terms and definitions used in this announcement shall have the same meaning as
ascribed to them in the Company's announcement dated 3 August 2023, unless
otherwise stated.

 

 

For Further Information:

 

 Sareum Holdings plc                              01223 497700

 Tim Mitchell, CEO                                ir@sareum.co.uk

 Lauren Williams, Head of Investor Relations

 Strand Hanson Limited (Nominated Adviser)        020 7409 3494

 James Dance / James Bellman

 Peel Hunt LLP (Joint Corporate Broker)           020 7418 8900
 James Steel / Patrick Birkholm

 Hybridan LLP (Joint Corporate Broker)            020 3764 2341

 Claire Noyce

 ICR Consilium (Financial PR)                     0203 709 5700

 Jessica Hodgson / Davide Salvi / Kumail Waljee

 

 

About Sareum

 

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing
next generation kinase inhibitors for autoimmune disease and cancer.

 

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases and has entered
Phase 1a/b clinical development with an initial focus on psoriasis.

 

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy.

 

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(http://www.sareum.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEGPUPWCUPCGUB